2 results about "Toxicity reduction" patented technology

This invention relates to an immunotoxin targeting hematologic malignancies and its application. The immunotoxin comprises a toxic molecule and a carrier. The toxic molecule is pumpkin protein or a mutant of pumpkin protein. The carrier contains an antibody, ligand, or polypeptide capable of binding to hematologic malignancies cells. The antibody comprises an antibody fragment or a small molecule antibody. This invention provides an immunotoxin targeting hematologic malignancies for the treatment of these malignancies. The immunotoxin using a pumpkin protein mutant as the toxic molecule exhibits enhanced specificity against hematologic malignancies cells with high target expression, significantly increased activity in killing target cells, and allows for a substantial reduction in dosage and toxicity. In summary, the immunotoxin targeting hematologic malignancies using a pumpkin protein mutant as the toxic molecule offers advantages in both synergistic effect and reduced toxicity, and has broad application prospects.

The application discloses a eutectic solvent of lidocaine and tocol, a preparation method and application thereof, and relates to the technical field of anesthetic preparations.The eutectic solvent is formed by removing hydrochloric acid from lidocaine hydrochloride and tocol through a supercritical preparation process; wherein the molar ratio of the lidocaine hydrochloride and the tocol is 1:1.The application first constructs a eutectic system by taking tocol as a key hydrogen bond acceptor and lidocaine hydrochloride, and removes hydrochloric acid synchronously through a supercritical preparation process in a reduced pressure process, so that the melting point of lidocaine is significantly reduced from about 77 DEG C to 15 DEG C, room temperature liquidization is realized, an unexpected 'fast-acting and long-acting' synergistic anesthetic effect and a safety advantage of'synergistic effect and toxicity reduction' are generated.The experiment shows that the transdermal absorption intensity and anesthetic duration of the eutectic solvent are obviously better than those of traditional preparations, and the eutectic solvent can reduce the blood plasma peak concentration and the risk of neurotoxicity.The preparation is suitable for clinical transdermal local anesthesia and intravenous general anesthesia.